AR043241A1 - Terapia combinada que comprende un derivado de indolpirrol-carbazol y otro agente antitumoral - Google Patents

Terapia combinada que comprende un derivado de indolpirrol-carbazol y otro agente antitumoral

Info

Publication number
AR043241A1
AR043241A1 ARP040100529A ARP040100529A AR043241A1 AR 043241 A1 AR043241 A1 AR 043241A1 AR P040100529 A ARP040100529 A AR P040100529A AR P040100529 A ARP040100529 A AR P040100529A AR 043241 A1 AR043241 A1 AR 043241A1
Authority
AR
Argentina
Prior art keywords
indolpirrol
combined therapy
antitumoral agent
carbazol derivative
another
Prior art date
Application number
ARP040100529A
Other languages
English (en)
Original Assignee
Pharmacia Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa
Publication of AR043241A1 publication Critical patent/AR043241A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Método para el tratamiento del cáncer en un sujeto que necesita dicho tratamiento, y dicho método comprende la administración al paciente de una cantidad terapéuticamente eficaz de edotecarina junto con capecitabina o docetaxel. Composiciones farmacéuticas y kit terapéutico que las contienen.
ARP040100529A 2003-02-21 2004-02-20 Terapia combinada que comprende un derivado de indolpirrol-carbazol y otro agente antitumoral AR043241A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000317A ITMI20030317A1 (it) 2003-02-21 2003-02-21 Terapia combinata comprendente un derivato dell'indolopirrolocarbazolo ed un altro agente antitumorale.

Publications (1)

Publication Number Publication Date
AR043241A1 true AR043241A1 (es) 2005-07-20

Family

ID=32894164

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040100529A AR043241A1 (es) 2003-02-21 2004-02-20 Terapia combinada que comprende un derivado de indolpirrol-carbazol y otro agente antitumoral

Country Status (10)

Country Link
EP (1) EP1599210A1 (es)
JP (1) JP2006518355A (es)
AR (1) AR043241A1 (es)
BR (1) BRPI0407642A (es)
CA (1) CA2516097A1 (es)
CL (1) CL2004000319A1 (es)
IT (1) ITMI20030317A1 (es)
MX (1) MXPA05008879A (es)
TW (1) TW200500073A (es)
WO (1) WO2004073719A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2596801B1 (en) * 2006-10-06 2018-05-02 Bavarian Nordic A/S Recombinant modified vaccinia ankara virus encoding a her-2 antigen for use in treating cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6441026B1 (en) * 1993-11-08 2002-08-27 Aventis Pharma S.A. Antitumor compositions containing taxane derivatives
WO2001062235A2 (en) * 2000-02-28 2001-08-30 Aventis Pharma S.A. A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer

Also Published As

Publication number Publication date
JP2006518355A (ja) 2006-08-10
EP1599210A1 (en) 2005-11-30
ITMI20030317A1 (it) 2004-08-22
TW200500073A (en) 2005-01-01
MXPA05008879A (es) 2005-10-05
WO2004073719A1 (en) 2004-09-02
CL2004000319A1 (es) 2005-04-22
CA2516097A1 (en) 2004-09-02
BRPI0407642A (pt) 2006-03-01

Similar Documents

Publication Publication Date Title
AR049985A1 (es) Tratamiento de combinacion para enfermedades malignas no hematologicas
ES2109899T1 (es) Metodo, composiciones y kits para aumentar la biodisponibilidad oral de agentes farmaceuticos.
AR060306A1 (es) Terapia de combinacion de anticuerpos contra ctla4
PA8588601A1 (es) Administracion combinada de una indolinona junto a un agente quimioterapeutico para el tratamiento de enfermedades de proliferacion celular
AR041725A1 (es) Prevencion, tratamiento de la enfermedad sinucleinopatica y composicion farmacologica
CO6361942A2 (es) Terapia de combinacion con epoxicetonas peptidicas
ES2080837T3 (es) Tratamiento de estados y enfermedades.
AR047841A1 (es) Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios
UY26456A1 (es) Compuestos que fijan la estructura g-cuadruplex de los telomeros, triazinas de aplicación de dichos compuestos, la utilización de dichos compuestos como productos farmacéuticos y las asociaciones terapéuticas que los incluyen.
NO20071426L (no) Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
AR042051A1 (es) Tratamiento combinado contra el cancer con un compuesto anti-cancerigeno activado por glutationa s- transferasa (gst) y otro tratamiento contra el cancer
CL2019002218A1 (es) Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
IS6558A (is) Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni
CO5590913A2 (es) Terapia de combinacion antivirica
AR048318A1 (es) Formulaciones de matriz orales que comprenden licarbazepina
BR0316057A (pt) Métodos de tratar, controlar ou prevenir um câncer especìfico e uma doença associada com angiogênese indesejada e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo e com a terapia de radiação, terapia hormonal, terapia biológica ou imunoterapia em um paciente sofrendo de um câncer especìfico, composição farmacêutica e kit
MX2022000430A (es) Administracion de agonista de sting e inhibidores de puntos de control.
BRPI0413410A (pt) co-administração de um polissacarìdeo com um agente quimioterapêutico para o tratamento de cáncer
EP1503748A4 (en) DRUGS TO REDUCE TAXAN-INDUCED NEUROTOXICITY
NO20064753L (no) Kombinasjonsterapi
NO20044498L (no) Kombinasjonsterapi for behandling av cancer
MX2022016406A (es) Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un inhibidor de hif-2 alpha y lenvatinib.
AR048806A1 (es) Uso de cariofilenos en la elaboracion de medicamentos y tratamiento de afecciones corporales de inflamacion y dolor inflamatorio
BR112022012081A2 (pt) Método para tratar câncer, kit, e, uso de uma combinação terapêutica

Legal Events

Date Code Title Description
FB Suspension of granting procedure